biostudies-literatureUnknown328(6)RESCUE BT Trial Investigators<h4>Importance</h4>Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa receptor, which reversibly inhibits platelet aggregation. It remains uncertain whether intravenous tirofiban is effective to improve functional outcomes for patients with large vessel occlusion ischemic stroke undergoing endovascular thrombectomy.<h4>Objective</h4>To assess the efficacy and adverse events of intravenous tirofiban before endovascular thrombectomy for acute ischemic stroke secondary to large vessel occlusion.<h4>Design, setting, and participants</h4>This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 55 hospitals in China, enrolling 948 patients with stroke and proximal intracranial large vessel occlusion presenting within 24 hours JAMA543-553https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364124biostudies-literatureEffect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.PMC9364124Zhang GDeng SXue DGuo ZHu ZZhang JHu WLiang YHu XZhang MWan YHao YShi ZZhang SKe YYan ZSu RHao ZGuo JGuo FDeng WYuan ZSang HZheng XRESCUE BT Trial InvestigatorsPu JXu CJin YJin ZYuan GYuan JHu JZeng HXu XZeng FZeng GLin MQi LLei LCao MMeng RQi JFu XDai WZhao WShuai JLei BTang KTang MZhao LYu TLi BTang TWei LNogueira RGYu YChang MZhou PNi HBai YZhou YZhou XZhou ZTian ZFu DPeng DLv FHong YCao WYu CHuang WYe SCao ZHuang XTian YZhu XHan JHan CYi DKong WQin CWu JHuang CWu MHuang JGe HWu DHuang LWang JWang LYue CSaver JLQiu ZWen HWang NXie FWang SWang TGu GSun DWen CShang XChen XChen SWang YWu WWu YSun JWu XYang HLi HYang JLi JXie YLi CLi FChen LLi RSun YLi LLu MLi ZYang YZuo JDu JYang QYang SLong CLiu JJiang LLuo ZJiang SLiu SLiu TGong ZMiao JLiu WLiu XLiu YSong KDing XLong WXu AZheng CZheng BSong BJu DZi WSong JDuan ZLuo JPan CZhang ZZhang YLuo WYan DLuo XLiu CLuo SLiu DFang LfalseEffect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.<h4>Importance</h4>Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa receptor, which reversibly inhibits platelet aggregation. It remains uncertain whether intravenous tirofiban is effective to improve functional outcomes for patients with large vessel occlusion ischemic stroke undergoing endovascular thrombectomy.<h4>Objective</h4>To assess the efficacy and adverse events of intravenous tirofiban before endovascular thrombectomy for acute ischemic stroke secondary to large vessel occlusion.<h4>Design, setting, and participants</h4>This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 55 hospitals in China, enrolling 948 patients with stroke and proximal intracranial large vessel occlusion presenting within 24 hours 2022-01-01T00:00:00Z2022 Aug2025-04-21T18:12:02.58Z2025-04-05T17:07:58.296ZS-EPMC93641243594347110.1001/jama.2022.12584